UNIVERSI
TÄ
TS-
BIBLIOTHEK
P
ADERBORN
Anmelden
Menü
Menü
Start
Hilfe
Blog
Weitere Dienste
Neuerwerbungslisten
Fachsystematik Bücher
Erwerbungsvorschlag
Bestellung aus dem Magazin
Fernleihe
Einstellungen
Sprache
Deutsch
Deutsch
Englisch
Farbschema
Hell
Dunkel
Automatisch
Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist
gegebenenfalls
nur via VPN oder Shibboleth (DFN-AAI) möglich.
mehr Informationen...
Universitätsbibliothek
Katalog
Suche
Details
Zur Ergebnisliste
Ergebnis 12 von 95
Datensatz exportieren als...
BibTeX
Novel inhibitors of urokinase‐type plasminogen activator and matrix metalloproteinase expression in metastatic cancer cell lines
International journal of cancer, 2004-07, Vol.110 (4), p.610-616
Cakarovski, Kristina
Leung, Jenny Y.
Restall, Christina
Carin‐Carlson, Anna
Yang, Eunice
Perlmutter, Patrick
Anderson, Robin
Medcalf, Robert
Dear, Anthony E.
2004
Volltextzugriff (PDF)
Details
Autor(en) / Beteiligte
Cakarovski, Kristina
Leung, Jenny Y.
Restall, Christina
Carin‐Carlson, Anna
Yang, Eunice
Perlmutter, Patrick
Anderson, Robin
Medcalf, Robert
Dear, Anthony E.
Titel
Novel inhibitors of urokinase‐type plasminogen activator and matrix metalloproteinase expression in metastatic cancer cell lines
Ist Teil von
International journal of cancer, 2004-07, Vol.110 (4), p.610-616
Ort / Verlag
Hoboken: Wiley Subscription Services, Inc., A Wiley Company
Erscheinungsjahr
2004
Quelle
Wiley Online Library - AutoHoldings Journals
Beschreibungen/Notizen
The plasminogen‐activating (PA) and matrix metalloproteinase (MMP) enzyme systems are implicated in proteolytic turnover of the extracellular matrix (ECM) associated with biologic processes including wound healing, inflammation and angiogenesis. Aberrant expression of components of the PA and MMP enzyme systems occurs in the pathogenesis of metastatic cancer. Oxamflatin (Ox), a novel hydroxamic acid derivative, inhibits u‐PA mRNA expression and proteolytic activity while simultaneously upregulating the expression of the natural inhibitor of u‐PA, plasminogen activator inhibitor type 2 (PAI‐2) in metastatic cancer cells. We have characterized the effects of Ox and a novel derivative, Metacept‐1 (MCT‐1), on PA and MMP‐mediated proteolysis and invasion in several metastatic tumor lines. Both compounds are able to inhibit u‐PA‐, MMP‐2‐ and MMP‐9‐mediated gene expression at low micromolar concentrations as well as u‐PA‐ and MMP‐mediated proteolysis as assessed by zymography, with MCT‐1 being the more effective of the 2 agents in some assays. Cellular invasion assays correlate with gene expression and zymography experiments identifying both Ox and MCT‐1 as able to inhibit invasion of metastatic cancer cell lines through matrigel at nanomolar concentrations, with MCT‐1 more effective than Ox in 2 of the 3 cancer cell lines assessed. © 2004 Wiley‐Liss, Inc.
Sprache
Englisch
Identifikatoren
ISSN: 0020-7136
eISSN: 1097-0215
DOI: 10.1002/ijc.20135
Titel-ID: cdi_proquest_miscellaneous_71889419
Format
–
Schlagworte
Antineoplastic agents
,
Biological and medical sciences
,
Cell Line, Tumor
,
Enzyme Inhibitors - pharmacology
,
Gene Expression Regulation, Neoplastic - drug effects
,
General aspects
,
histone deacetylase inhibitors (HDACi)
,
Humans
,
Hydroxamic Acids - pharmacology
,
matrix metalloproteinase
,
Matrix Metalloproteinase Inhibitors
,
Medical sciences
,
metacept‐1(MCT‐1)
,
Neoplasm Invasiveness
,
Neoplasm Metastasis - drug therapy
,
Neoplasm Metastasis - pathology
,
oxamflatin (Ox)
,
Pharmacology. Drug treatments
,
RNA, Messenger - analysis
,
Sulfonamides - pharmacology
,
Urokinase-Type Plasminogen Activator - antagonists & inhibitors
,
Urokinase-Type Plasminogen Activator - genetics
,
urokinase‐type plasminogen activatar
Weiterführende Literatur
Empfehlungen zum selben Thema automatisch vorgeschlagen von
bX